AVR

Upcoming Meetings: Cantor Fitzgerald will host meetings in New York on April 8 and in Boston on April 9.

Investment Opportunities: The article promotes Analyst Top Stocks for recommended stocks by Wall Street analysts and highlights the Smart Investor Newsletter for weekly stock picks.

Milestone Achievement: Anteris Technologies has successfully treated over 100 patients with its DurAVR Transcatheter Heart Valve (THV), showcasing significant safety and efficacy in treating severe aortic stenosis, including complex cases.

Future Plans: The company is set to commence the pivotal trial for the DurAVR THV in Q3 2025, pending FDA approval, aiming to further validate its innovative heart valve technology.

DurAVR Transcatheter Heart Valve Results: Anteris Technologies announced positive one-year results for its DurAVR Transcatheter Heart Valve (THV) System, showcasing a favorable hemodynamic profile and zero instances of prosthesis-patient mismatch in small annuli patients, which is significant for long-term patient outcomes.

Future Plans and Clinical Evidence: The data will be included in the Investigational Device Exemption (IDE) submission to the U.S. FDA as Anteris prepares for pivotal trials, reinforcing the transformative potential of the DurAVR THV in treating aortic stenosis.

Analyst Ratings: Frank Takkinen from Lake Street maintains a Buy rating on Anteris Technologies Global Corp. with a price target of $20.00, while the stock currently trades at $6.83 and has a consensus Strong Buy rating with a target of $16.50.

Market Performance: Anteris Technologies has experienced a one-year high of $8.79 and a low of $5.10, with an average trading volume of 131.8K shares.

Financial Highlights: Anteris Technologies reported a net loss of $76 million for 2024, despite generating $2.7 million in sales, and concluded the year with a strong cash position of $70.5 million following a successful IPO that raised $88.8 million.

Product Development Update: The company is preparing to initiate the pivotal trial for its DurAVR Transcatheter Heart Valve system, having completed early feasibility studies and presented positive clinical data at major medical conferences, aiming for FDA submission in Q1 2025.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

Analyst Coverage: Barclays analyst Matt Miksic has initiated coverage on Anteris Technologies Global Corp. (AVR) with a positive rating and a forecast price of $22, highlighting the potential of its DurAVR valve system to capture 4%-5% of the U.S. TAVR market by 2030.

Market Insights: Despite a slowdown in TAVR market growth, the analyst views it as underpenetrated, with DurAVR expected to outperform competitors in hemodynamics and long-term durability due to its innovative design and technology.

Analyst Ratings Updates: Top Wall Street analysts have initiated coverage on several companies, including Coca-Cola (Overweight rating, price target $74), JPMorgan Chase (Hold rating, price target $260), and Ascendis Pharma (Buy rating, price target $196).

Stock Performance Insights: The current share prices for these companies are below the analysts' price targets, indicating potential growth opportunities; Coca-Cola closed at $60.81, JPMorgan at $240.85, and Ascendis Pharma at $140.28.